AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the presentation of in vivo preclinical data showing AB-PA01 reduces biofilm in a Pseudomonas aeruginosa preclinical model. The data were presented at the Australian Society of Otolaryngology Head and Neck Surgery 68 th Annual Scientific Meeting, being held March 9-11, 2018 in Perth, Western Australia. The presentation, titled "Efficacy and safety of a Pseudomonas aeruginosa bacteriophage cocktail in a sheep model of rhinosinusitis" will be delivered by Dr. Stephanie Fong on Saturday, March 10, 2018, at 1:40 p.m. local time in Crown Ballroom 1, Concurrent Session 10 - Rhinology, at the Crown Perth Convention Centre. "The data presented demonstrate the potential of bacteriophage therapeutics by clearly showing AB-PA01's effectiveness in reducing biofilm in vivo, a major obstacle in the treatment of Pseudomonas aeruginosa and its associated symptoms," said Peter-John Wormald, M.D., Professor of Otolaryngology Head & Neck Surgery at the University of Adelaide and Principal Investigator for AmpliPhi's already completed Phase 1 study, "I believe bacteriophage therapeutics hold much promise and this study adds to the growing body of supportive evidence." A sheep rhinosinusitis model was adapted to simulate Pseudomonas aeruginosa infection in sheep frontal sinuses. To assess efficacy, after a 7-day biofilm formation period, sheep received twice-daily flushes of AB-PA01 or saline for one week. Biofilm quantitation on the frontal sinus mucosa was performed using BacLight LIVE/DEAD stain. The study showed a statistically significant reduction in biofilm biomass with AB-PA01 compared to control (p<0.05). No safety concerns were noted. About AmpliPhi Biosciences AmpliPhi Biosciences Corporation is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology. AmpliPhi's lead product candidates target multidrug-resistant Staphylococcus aureus and Pseudomonas aeruginosa, which are included on the WHO's 2017 Priority Pathogens List. Phage therapeutics are uniquely positioned to address the threat of antibiotic-resistance as they can be precisely targeted to kill select bacteria, have a differentiated mechanism of action, can penetrate and disrupt biofilms (a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics and have been shown to restore antibiotic sensitivity to drug-resistant bacteria. For more information visit www.ampliphibio.com.